



GETTING THE WORLD VACCINATED AGAINST COVID-19

OCTOBER 2021 STATISTICS UPDATE



PROGRESS IN PRODUCING VACCINES IS HIGH. FOCUS SHOULD NOW BE ON DISTRIBUTION AND ADMINISTERING


In two months (December 2021), global COVID-19 vaccine production will surpass **12 billion**. Current production stands at **1.2 billion doses a month**. Success in fighting COVID-19 then relies on distributing and administering these doses globally. Industry is committed to support as much as possible. Until 1 October 2021, **558 million donated doses** have been received by countries needing them.



Industry has delivered: developing COVID-19 vaccines and ramping up production to over 12 billion doses by December 2021 via unparalleled R&D efforts and levels of cooperation, including via over 329 collaborations.

WE HAVE SAFE AND EFFECTIVE COVID-19 VACCINES TODAY BECAUSE OF LONG-TERM INVESTMENTS IN INNOVATION

New vaccine technologies, now used in the fight against COVID-19, are the result of decades of R&D. Their application to COVID-19 in 2020 was made possible by strong cooperation between academics, industry, regulators and governments.



Innovation and R&D continue to be important to fight emerging COVID-19 Variants of Concern (VoC) and are vital to future pandemic preparedness.


COVID-19 VACCINE PRODUCTION IS COMPLICATED, NEEDS REGULATORY APPROVAL AND REQUIRES EXTENSIVE QUALITY CONTROL

NUMBER OF APPROVED VACCINES AROUND THE WORLD



As of October 2021, there are **14 approved vaccines** and **143 vaccine candidates** in clinical development with over **200 clinical trials** currently ongoing.

Source: McGill COVID-19 Vaccine Tracker Team (October 2021)



70% of the vaccine production time is dedicated to quality control and testing. Knowing the ingredients of a vaccine and how to combine them is not sufficient: expertise and experience matter, which is why the 329 voluntary licensing agreements are key.


TRADE POLICY SUPPORTING GLOBAL VACCINE EXPORTS IS A KEY DRIVER FOR VACCINE EQUITY

TRADE PROTECTIONISM IS STILL INCREASING



Source: Global Trade Alert (24 September 2021)

COVID-19 VACCINE DOSES PRODUCED AND EXPORTED (JUL/OCT)




Source: Airfinity (October 2021)

Producing one vaccine can require 280 components from 86 suppliers in 19 countries. That is why trade openness is vital for global supply chains to allow COVID-19 vaccine production and exports. Governments should eliminate trade barriers that impede the distribution of critical supplies and vaccines across borders, for example through the Trade and Health Initiative (TAHI) at the WTO.


HEALTHCARE SYSTEM ABSORPTIVE CAPACITIES AND VACCINE HESITANCY ARE BARRIERS TO VACCINE ACCESS AND SUCCESS

HEALTHCARE ACCESS AND QUALITY (HAQ) INDEX



Source: The Lancet (2018)

COVID-19 VACCINE WILLINGNESS VARIES SIGNIFICANTLY BY COUNTRY



Success of COVID-19 vaccine roll-outs depends on national policies' abilities to ensure citizens receive the vaccines. High levels of vaccine hesitancy can have significant negative effect.

Source: Gallup (2020), Created with Datawrapper

With production no longer being the bottleneck, healthcare system preparedness for COVID-19 vaccine roll-outs and high levels of vaccine confidence are key factors to get people vaccinated. But these are still lacking in parts of the world.

INTELLECTUAL PROPERTY – PART OF THE SOLUTION NOT PART OF THE PROBLEM

IP incentivises long-term R&D (200 clinical trials are currently ongoing)

IP allowed for the first COVID-19 vaccine approval within 326 days; the fastest ever

IP facilitates ramping up production through use of best available infrastructure for scaling up

IP facilitates effective collaboration and voluntary technology transfers

IP supports vaccine confidence by reducing the risk of counterfeit vaccines

IP allows for global preparedness for new Variants of Concern and future pandemics

FIVE STEPS TO URGENTLY ADVANCE COVID-19 VACCINE EQUITY



OPTIMISE PRODUCTION



ELIMINATE TRADE BARRIERS



STEP UP DOSE SHARING



SUPPORT COUNTRY READINESS



DRIVE FURTHER INNOVATION